Aura Biosciences, Inc. (AURA) — SEC Filings

Latest SEC filings for Aura Biosciences, Inc. (AURA), explained in plain English.

Sentiment Overview: 1 bearish, 26 neutral, 3 mixed

Recent Filings (30)

• S-8 Filing — S-8 · 2026-03-30T07:27:38-04:00 [neutral]
• Aura Biosciences Faces 'Going Concern' Amidst Bel-sar's Pivotal Trials — 10-K · 2026-03-30T07:15:29-04:00 [mixed] Risk: high
  Aura Biosciences, Inc. (AURA) reported significant net losses since inception and anticipates continued losses, leading its auditors to issue a "going concern"
• Aura Biosciences Files 8-K on Financials and Operations — 8-K · 2026-03-30T07:05:19-04:00 [neutral] Risk: medium
  Aura Biosciences, Inc. filed an 8-K on March 30, 2026, reporting on its results of operations and financial condition, as well as other events. The filing inclu
• Aura Biosciences' Losses Widen on Soaring R&D for Lead Candidate — 10-Q · 2025-11-13T00:00:00.000Z [mixed] Risk: high
  Aura Biosciences, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $80.632 million, up from $61.085 milli
• Aura Biosciences' Net Loss Widens Amid R&D Surge, Bolstered by $70M Offering — 10-Q · 2025-08-13T00:00:00.000Z [mixed] Risk: high
  Aura Biosciences, Inc. (AURA) reported a significant increase in net loss for the six months ended June 30, 2025, reaching $54.502 million, up from $40.043 mill
• Aura Biosciences Files 8-K on Shareholder Vote Matters — 8-K · 2025-06-18T00:00:00.000Z [neutral] Risk: low
  Aura Biosciences, Inc. filed an 8-K on June 18, 2025, reporting on a submission of matters to a vote of security holders that occurred on June 17, 2025. The fil
• 8-K Filing — 8-K · 2025-05-16T00:00:00.000Z [neutral]
• Aura Biosciences Q1 2025 Update — 10-Q · 2025-05-15T00:00:00.000Z [neutral] Risk: medium
  Aura Biosciences, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial condition, including its cash and cash equival
• Aura Biosciences Files 2025 Proxy Statement — DEF 14A · 2025-04-24T00:00:00.000Z [neutral] Risk: low
  Aura Biosciences, Inc. filed its definitive proxy statement (DEF 14A) on April 24, 2025, for its fiscal year ending December 31, 2024. The filing pertains to th
• Aura Biosciences Reports Officer/Director Changes & Compensatory Info — 8-K · 2025-04-02T00:00:00.000Z [neutral] Risk: medium
  Aura Biosciences, Inc. filed an 8-K on April 2, 2025, reporting events as of March 31, 2025. The filing primarily concerns the departure of directors or certain
• 10-K Filing — 10-K · 2025-03-24T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• Aura Biosciences Q3 2024 Update — 10-Q · 2024-11-12T00:00:00.000Z [neutral] Risk: medium
  Aura Biosciences, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial performance and business operations, inclu
• SC 13G/A Filing — SC 13G/A · 2024-11-12T00:00:00.000Z [neutral]
• SC 13G Filing — SC 13G · 2024-11-08T00:00:00.000Z [neutral]
• SC 13G Filing — SC 13G · 2024-10-22T00:00:00.000Z [neutral]
• Aura Biosciences Files 8-K — 8-K · 2024-10-17T00:00:00.000Z [neutral] Risk: low
  Aura Biosciences, Inc. filed an 8-K on October 17, 2024, reporting on other events and financial statements. The filing does not contain specific details about
• Aura Biosciences Appoints New Director, Adjusts Executive Pay — 8-K · 2024-09-27T00:00:00.000Z [neutral] Risk: medium
  Aura Biosciences, Inc. announced on September 23, 2024, changes in its board of directors and executive compensation. Specifically, Dr. David E. Johnson has bee
• Aura Biosciences Files 8-K — 8-K · 2024-09-12T00:00:00.000Z [neutral] Risk: low
  Aura Biosciences, Inc. filed an 8-K on September 12, 2024, to report on other events and financial statements. The filing does not contain specific financial fi
• Aura Biosciences Files Q2 2024 10-Q — 10-Q · 2024-08-08T00:00:00.000Z [neutral] Risk: medium
  Aura Biosciences, Inc. filed its 10-Q for the period ending June 30, 2024. The company, focused on biological products, reported financial information for the s
• Aura Biosciences Files 8-K with Corporate Updates — 8-K · 2024-06-21T00:00:00.000Z [neutral] Risk: low
  Aura Biosciences, Inc. filed an 8-K on June 21, 2024, reporting events that occurred on June 20, 2024. The filing indicates changes to the company's articles of
• Aura Biosciences 2024 Annual Meeting Proxy Supplement Filed — DEFA14A · 2024-06-14T00:00:00.000Z [neutral] Risk: low
  Aura Biosciences, Inc. is filing a supplemental proxy statement for its 2024 Annual Meeting of Stockholders, scheduled for June 20, 2024. This filing provides a
• Aura Biosciences Files 8-K Report — 8-K · 2024-06-04T00:00:00.000Z [neutral] Risk: low
  On June 4, 2024, Aura Biosciences, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating up
• Aura Biosciences Files 8-K for Operations Update — 8-K · 2024-05-09T00:00:00.000Z [neutral] Risk: low
  Aura Biosciences, Inc. filed an 8-K on May 9, 2024, to report on its results of operations and financial condition, as well as to file financial statements and
• Aura Biosciences Announces 2024 Annual Meeting of Stockholders on June 20, 2024 — DEF 14A · 2024-04-25T00:00:00.000Z [neutral] Risk: low
  Aura Biosciences, Inc. (AURA) filed a Proxy Statement (DEF 14A) with the SEC on April 25, 2024. Aura Biosciences, Inc. will hold its 2024 Annual Meeting of Stoc
• Aura Biosciences Announces Board and Executive Changes — 8-K · 2024-04-15T00:00:00.000Z [neutral] Risk: medium
  Aura Biosciences, Inc. announced on April 12, 2024, changes in its board of directors and executive compensation arrangements. Specifically, the company reporte
• Aura Biosciences, Inc. Files 2023 Annual Report on Form 10-K — 10-K · 2024-03-27T00:00:00.000Z [neutral] Risk: medium
  Aura Biosciences, Inc. (AURA) filed a Annual Report (10-K) with the SEC on March 27, 2024. Aura Biosciences, Inc. filed its annual report on Form 10-K for the f
• SC 13G/A Filing — SC 13G/A · 2024-02-14T00:00:00.000Z [neutral]
• Adage Capital Partners Cuts Aura Biosciences Stake to 9.9% — SC 13G/A · 2024-02-07T00:00:00.000Z [bearish]
  Adage Capital Partners, L.P. filed an amended SC 13G/A on February 7, 2024, disclosing its ownership in Aura Biosciences, Inc. As of December 31, 2023, Adage Ca
• Aura Biosciences Files 8-K, Confirms Emerging Growth Status — 8-K · 2024-01-08T00:00:00.000Z [neutral]
  Aura Biosciences, Inc. filed an 8-K on January 8, 2024, indicating an 'Other Events' disclosure. This filing, while not detailing specific financial transaction